Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma-Reference-Cited by-同舟云学术

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

Published:2019-10-30 Issue:21 Volume:3 Page:3248-3260
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Schmidts Andrea¹²^ORCID,Ormhøj Maria¹³^ORCID,Choi Bryan D.¹⁴,Taylor Allison O.¹,Bouffard Amanda A.¹,Scarfò Irene¹²^ORCID,Larson Rebecca C.¹²^ORCID,Frigault Matthew J.¹²,Gallagher Kathleen¹⁵,Castano Ana P.¹,Riley Lauren S.¹,Cabral Maria L.¹,Boroughs Angela C.¹²,Velasco Cárdenas Rubí M.-H.⁶⁷⁸,Schamel Wolfgang⁶⁷⁸,Zhou Jing⁹,Mackay Sean⁹,Tai Yu-Tzu²¹⁰¹¹,Anderson Kenneth C.²¹⁰¹¹,Maus Marcela V.¹²^ORCID

Affiliation:

1. Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA;

2. Department of Medicine, Harvard Medical School, Boston, MA;

3. Department of Clinical Immunology, University of Southern Denmark, Odense, Denmark;

4. Department of Neurosurgery and

5. Department of Pathology, Harvard Medical School, Boston, MA;

6. Department of Immunology, Faculty of Biology,

7. Center for Biological Signaling Studies (BIOSS), and

8. Center for Integrative Biological Signaling Studies (CIBSS), University of Freiburg, Freiburg, Germany;

9. Isoplexis, Branford, CT; and

10. LeBow Institute for Myeloma Therapeutics and

11. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Abstract

Key PointsA trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR. T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of MM.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/21/3248/1505873/advancesadv2019000703.pdf

Reference77 articles.

1. Multiple myeloma;Palumbo;N Engl J Med,2011

2. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol,2016

3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

4. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018;Kumar;J Natl Compr Canc Netw,2018

5. The T-body approach: potential for cancer immunotherapy;Eshhar;Springer Semin Immunopathol,1996

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble B‐cell maturation antigen in multiple myeloma;American Journal of Hematology;2024-01-25

2. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma;Nature Communications;2023-11-18

3. Genetic retargeting of E3 ligases to enhance CAR T cell therapy;Cell Chemical Biology;2023-11

4. Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy;Frontiers in Immunology;2023-09-18

5. Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment;iScience;2023-09